Australia’s medicines regulator, the Therapeutic Goods Administration (TGA), issues a new safety warning for several GLP-1 receptor agonist (GLP-1 RA) medicines used for type 2 diabetes and weight management. The TGA says product information for some therapies—including brands such as Ozempic, Wegovy and Mounjaro—has been updated to include a warning about a rare but severe eye disorder that can lead to loss of vision. The Guardian reports the condition is NAION (non-arteritic anterior ischemic optic neuropathy) and describes the update as being based on safety concerns identified after links were found between GLP-1 medicines and the disorder.
Multiple outlets summarise that the regulator’s warning applies to commonly used GLP-1 medicines in Australia, including Ozempic, Wegovy and Mounjaro, and also references Saxenda in the broader list of affected products. The Guardian states there have been reports of 36 cases linked to these medicines. The TGA’s communications focus on informing prescribers and patients about the potential risk and the need to consider eye symptoms in relevant clinical contexts.
